AU2010232915A1 - Formulation for inducing broadly reactive neutralizing anti-HIV antibodies - Google Patents

Formulation for inducing broadly reactive neutralizing anti-HIV antibodies Download PDF

Info

Publication number
AU2010232915A1
AU2010232915A1 AU2010232915A AU2010232915A AU2010232915A1 AU 2010232915 A1 AU2010232915 A1 AU 2010232915A1 AU 2010232915 A AU2010232915 A AU 2010232915A AU 2010232915 A AU2010232915 A AU 2010232915A AU 2010232915 A1 AU2010232915 A1 AU 2010232915A1
Authority
AU
Australia
Prior art keywords
ligand
mper
trl
tnd
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010232915A
Other languages
English (en)
Inventor
S. Munir Alam
Barton F. Haynes
Moses D. Sekaran
Xiaoying Shen
Georgia Tomaras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of AU2010232915A1 publication Critical patent/AU2010232915A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010232915A 2009-04-03 2010-04-05 Formulation for inducing broadly reactive neutralizing anti-HIV antibodies Abandoned AU2010232915A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16662509P 2009-04-03 2009-04-03
US61/166,625 2009-04-03
PCT/US2010/001017 WO2010114628A2 (en) 2009-04-03 2010-04-05 Formulation for inducing broadly reactive neutralizing anti-hiv antibodies

Publications (1)

Publication Number Publication Date
AU2010232915A1 true AU2010232915A1 (en) 2011-10-20

Family

ID=42828908

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010232915A Abandoned AU2010232915A1 (en) 2009-04-03 2010-04-05 Formulation for inducing broadly reactive neutralizing anti-HIV antibodies

Country Status (6)

Country Link
US (1) US9402917B2 (https=)
EP (1) EP2413951A4 (https=)
JP (1) JP2013505201A (https=)
AU (1) AU2010232915A1 (https=)
CA (1) CA2757240A1 (https=)
WO (1) WO2010114628A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2139516A4 (en) * 2007-04-13 2011-06-29 Univ Duke METHOD FOR INDUCING NEUTRALIZING ANTIBODY AGAINST HIV
US20120070488A1 (en) * 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20140322262A1 (en) * 2007-09-28 2014-10-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
CA2757240A1 (en) 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
WO2011106100A2 (en) * 2010-02-25 2011-09-01 Duke University Method of inducing the production of protective anti-hiv-1 antibodies
US20140093556A1 (en) * 2011-01-28 2014-04-03 Sanofi Pasteur Sa Immunological Compositions Against HIV
WO2014020205A2 (es) * 2012-07-31 2014-02-06 Universidad De Granada Inmunógenos anti-vih mejorados
CA2889064A1 (en) 2012-10-19 2014-04-24 The Council Of The Queensland Institute Of Medical Research Improved human herpesvirus immunotherapy
US10076567B2 (en) * 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
WO2024097957A1 (en) * 2022-11-03 2024-05-10 Duke University Novel antibodies for hiv and methods of making and using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020141A1 (en) 1993-03-11 1994-09-15 The University Of Southern California Therapeutic strategies for immunoinfective cluster virus infections
ES2204919T3 (es) 1993-05-27 2004-05-01 Entremed, Inc. Composiciones y procedimientos de tratamiento del cancer y de enfermedades hiperproliferativas.
JPH10504798A (ja) 1994-03-14 1998-05-12 ユニバーシティー オブ サウザーン カリフォルニア Ｈｉｖ−１感染の診断方法および処置方法
US6156337A (en) 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1250933A1 (en) 2001-04-17 2002-10-23 Istituto Superiore di Sanità Vaccines including as an adjuvant high dose type I IFN
AU2003300184B8 (en) * 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
EP1613643A4 (en) 2003-03-27 2009-10-28 Sudhir Paul LUPUS ANTIBODIES FOR THE PASSIVE IMMUNE THERAPY OF HIV / AIDS
US20080057075A1 (en) 2005-04-12 2008-03-06 Haynes Barton F Method of inducing neutralizing antibodies to human immunodeficiency virus
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2139516A4 (en) * 2007-04-13 2011-06-29 Univ Duke METHOD FOR INDUCING NEUTRALIZING ANTIBODY AGAINST HIV
BRPI0811228A2 (pt) * 2007-05-24 2014-10-21 Glaxonsmithkline Biolog S A Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica.
US20120070488A1 (en) 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20140322262A1 (en) 2007-09-28 2014-10-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2009111304A2 (en) 2008-02-29 2009-09-11 President And Fellows Of Harvard College A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
WO2010045613A1 (en) 2008-10-16 2010-04-22 New York Blood Center Immunoenhancer-linked oligomeric hiv vaccines
AU2010232916A1 (en) 2009-04-03 2011-10-27 Children's Medical Center Corporation Formulation
CA2757240A1 (en) 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies

Also Published As

Publication number Publication date
EP2413951A2 (en) 2012-02-08
US9402917B2 (en) 2016-08-02
US20120128758A1 (en) 2012-05-24
WO2010114628A3 (en) 2011-03-10
CA2757240A1 (en) 2010-10-07
JP2013505201A (ja) 2013-02-14
EP2413951A4 (en) 2015-05-20
WO2010114628A9 (en) 2010-11-25
WO2010114628A2 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
US9402917B2 (en) Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions
Montero et al. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design
US10588960B2 (en) Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
Dennison et al. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41
Matyas et al. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes
US20150147387A1 (en) Method of inducing antibodies to human immunodeficiency virus involving the administration of mper peptide-liposome conjugates
Bi et al. An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses
ES2366185T3 (es) Vacunas de péptidos sintéticas para vih: el epítopo de cbd como un inmunógeno eficaz para provocar anticuerpos ampliamente neutralizantes contra el vih.
US10076567B2 (en) MPER-liposome conjugates and uses thereof
US20080057075A1 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
Koornneef et al. CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits
Yu et al. The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent
EP2694533A2 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
US20220040290A1 (en) Compositions comprising supramolecular nanofiber hiv envelopes and methods for their use
US20110159037A1 (en) Methods of treating and protecting against human immunodeficiency virus
Wegmann et al. A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment
US20250073328A1 (en) Compositions and methods for treating or preventing hiv infection
CN101588813A (zh) 诱导人类免疫缺陷病毒的中和抗体的方法
Melnychuk Optimization of an HIV-1 clade C DNA vaccine
Watson Lipopeptide immunogens targeting the membrane proximal region of HIV-1 gp41
AU2014202366A1 (en) Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted